SIRO Clinpharm and Jai Research Foundation partner to offer drug-development solution

SIRO Clinpharm and Jai Research Foundation (JRF) have partnered to offer an end-to-end drug development solution, the companies said in a joint statement.

The statement also notified that SIRO focuses on patient studies and support trials from phase-II to phase-IV, whereas JRF offers GLP-compliant, customer-focussed, highly interactive services in the fields of toxicology, ecotoxicology, chemistry, environmental fate and metabolism, and other regulatory testing requirements. JRF is well-recognised for its expertise in genetic toxicology, repeat dose toxicology, (including the inhalation route), reproductive toxicology, with strong bioanalytical support to assess not only systemic exposure, but also product-specific immunotoxicity, biomarker assessment using HPLC-MS/MS, flow cytometry, and related state-of-the-art equipment. This arrangement will help SIRO to expand their offerings with comprehensive services, to their expanded pool of clients.

Commenting on the agreement, Akshay Daftary, Director, SIRO Clinpharm, said, “Strategic alliances are always mutually beneficial, fruitful, and, in our case, both the alliances have been a strong testimony to it. The agreement with JRF resonates with the company’s firm belief and vision of providing end-to-end solutions. The agreement would definitely boost SIRO’s presence across geographies like Japan, EU, LatAm countries, Canada, and the USA.”

Adding to it, Dr Sameer Navalgund, Director, JRF-Global, said, “The pre-clinical testing is akin to an engine for the safety assessment. The needs of their sponsors stand provided with well-calibrated scientific solutions, in respect of potential obstacles during clinical testing. The interpretation of the pre-clinical trials at JRF could offer indications to SIRO, to build up additional endpoints during the clinical trials. JRF’s reputed and well-received preclinical studies and interpretations will enable SIRO to stand benefitted in designing the trial protocols with a differentiation against the conventional service providers. With this agreement, both the companies stand to benefit, with their pooled mutual scientific talent and their capabilities to offer comprehensive solutions to their mutual sponsors.”